100

What 100 does

株式会社100 (ワンダブルオー / 100 Inc.) is a Kyoto-based femtech startup founded in March 2023 by Hiroko Yamagami, a former pharmaceutical MR and corporate planning executive, to address Japan's low breast cancer screening rate (47.4%, the lowest among OECD countries). The company's core product is NCT (New generation Cancer Test), a pain-free breast cancer screening platform that uses prone-position ultrasound imaging and is positioned for deployment at non-medical venues such as cafes, shopping malls, parks, and corporate offices. The business model is protected by Japanese business model patent No. 7289422, granted June 2023, covering the non-medical-facility testing concept with aftercare support.

NCT is currently pre-commercial at scale; the company monetizes through a hybrid stack: (1) direct-to-consumer test kits and home mineral-balance kits sold via its BASE online shop, (2) B2B corporate wellness seminars and breast cancer awareness events priced per event (named clients include Taiju Life Insurance, Mizkan Holdings, Kadoriru Nishida, Daiwa Lease), and (3) the FEMTECH& sub-brand event platform co-hosted with Wacal Lab and partners such as Madame FIGARO and Mellow., targeting women aged 30s–60s, corporate HR departments, and local governments. Distribution channels span regional pop-ups (Welpa at Shinsaibashi PARCO, AEON Mall Wakayama), the BASE e-commerce storefront, and corporate direct sales.

The company's operating footprint is currently Japan-focused (Kansai home base plus Kanto/Kansai pop-ups, with online nationwide reach), supported by government validation through Kyoto City Startup Social Challenge, Kyoto Prefecture Female Empowerment Program, and Next Innovator. Registered capital is 1M JPY (~$6,700), and the only known external funding is a 2023 CAMPFIRE crowdfunding campaign targeting 10M JPY. No institutional venture funding, revenue figures, or headcount are disclosed.

Name

100

Legal name

株式会社 100（100 Inc.）

Website

https://100onewo.com

Company type

Private

Founded year

2023

Operating status

Operating

Short description

100 (ワンダブルオー) is a Kyoto-based femtech startup operating the NCT platform for pain-free breast cancer screening at non-medical venues, serving Japanese women 30s–60s, corporate wellness programs, and local governments via test kits, seminars, and FEMTECH& events.

Ownership category

akta.pro rank

Product category

Women's Health Screening Services

NAICS

Medical Laboratories (621511), Medical and Diagnostic Laboratories (62151)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Remote Diagnostics & Home Testing Devices (Connected POC/At-Home Diagnostic Readers) (HLAHACAL)

akta.pro secondary industries

Home-Use & OTC Rapid Self-Tests (Consumer POCT kits) (HLAHAOAK), Personal Medical Devices & Home Diagnostics (Thermometers, Blood Pressure Monitors, Glucose Meters, Rapid Tests) (CRADAMAK), Remote Diagnostics & Point-of-Care (Connected Testing, Home Lab Devices) (HLACAPAK)

Keywords

• Breast cancer screening
• Femtech services
• Corporate wellness seminars
• Cancer testing platform
• Women's health consulting

Headquarters

HQ city

Kyoto

HQ country

Japan

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B and B2C

Offering type

Services

Cost components

Personnel, Marketing or Sales, Operations, Technology or R&D, Others

Revenue model

1. Product Sales: Sale of breast cancer risk test kits, mineral test kits, and other health screening products through BASE online shop and pop-up stores.
2. Event Planning and Consulting Services: Corporate wellness seminars, breast cancer awareness seminars for companies, event planning and management for Femtech events.
3. NCT Service Platform: Next-generation cancer testing services offered at non-medical facilities, with appointment booking through smartphone and results delivery via mobile app.

Pricing tiers

Go-to-market motion2 records

Distribution channels5 records

Marketing channels5 records

Core offering

株式会社100 (100 Inc.) operates the NCT (New generation Cancer Test) platform, a next-generation cancer testing service that delivers pain-free breast cancer screening at non-medical locations such as cafes, shopping malls, and parks using ultrasound and other non-invasive modalities. The company also sells home-use test kits (breast cancer risk and mineral balance) through its BASE online shop, runs corporate breast cancer awareness seminars for enterprise clients, and curates the FEMTECH& branded event series to drive women's health awareness.

Product overview

株式会社100 (100 Inc.) operates as a healthcare/femtech startup offering NCT (New generation Cancer Test) - a next-generation cancer testing platform. The core offering includes pain-free breast cancer screening services using innovative technology (prone-position ultrasound) available outside medical institutions at accessible locations. The company also sells home-use testing kits (breast cancer risk and mineral balance), operates the FEMTECH＆ sub-brand for femtech events and projects, and provides well-being consulting services. The product portfolio centers on democratizing cancer screening through the NCT platform while expanding reach via the FEMTECH＆ concept brand and supporting health-related events and seminars.

Differentiator

Problem solved

Functional benefit

Products and services

• NCT (New generation Cancer Test) Cancer Screening Service Pain-free breast cancer screening service using ultrasound imaging in prone position and other non-invasive modalities, delivered at cafes, shopping malls, and other daily-accessible non-medical locations with 30-minute testing and smartphone booking/results. Targets women who delay or avoid traditional mammography due to pain, embarrassment, time constraints, or facility access issues.
• NCT Home-use Test Kits (Breast Cancer Risk & Mineral Balance) Direct-to-consumer test kits for at-home breast cancer risk assessment and mineral balance measurement, providing women with convenient, accessible health screening options outside clinical settings.
• Corporate Wellness Seminars (B2B) B2B breast cancer awareness seminars, Pink Ribbon Month initiatives, and employee wellness programs delivered to corporate HR departments and management, targeting female employees and addressing low screening rates in Japan's workforce.
• Well-being Consulting & Event Planning Services Planning, sales, and consulting services for well-being and Femtech initiatives, including event planning and management, Femtech event production, and health promotion program consulting for corporations and communities.

Quantifiable outcome

• 日本的乳がん検査受診率は47.4%にとどまり、OECD加盟国中最下位
• +2 more outcomes

Named customers5 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature3 records

Partnerships

Nine partnerships are on record, tiered minor, major, strategic and core.

• フィガロジャボン Business with Attitude (BWA)minorGTM or Marketing Partner · 14 November 2025Media partner for 3rd anniversary FEMTECH& WAKEWAKE Project event. Women's entrepreneurship media platform partnership.
• 大樹生命株式会社 (Taiju Life Insurance)minorGTM or Marketing Partner · 6 October 2025Breast cancer screening seminar at Taiju Life Kyoto sales office. Corporate wellness initiative for insurance company employees.
• 大和リース株式会社 (Daiwa Lease)majorStrategic or Co-development Partner · 25 January 2025Demonstration project partner for adding wellness value to parks. Co-hosted events at Omiya Traffic Park in Kyoto testing park as new health infrastructure. Partnered for Pink Ribbon Month breast cancer awareness seminar.
• 京都府 (Kyoto Prefecture)majorOthers · 20 December 2024Government backer for female health events. Supported 年はじめ Petit Tea Event for Women's Health as co-host. Backed by prefecture for women's empowerment initiatives.
• 心斎橋PARCO / Welpa (Welpa Medical Wellness Mall)majorChannel Partner/ Reseller/ Distributor · 18 November 2024Pop-up store host for FEMTECH& event at Shinsaibashi PARCO 10F medical wellness area. December 2024 - January 2025 retail and event partnership.
• Mellow. (メロウドット)strategicStrategic or Co-development Partner · 18 November 2024Collaboration brand for FEMTECH& diversity-themed pop-up store at PARCO. Genderless intimate zone skincare brand partnership for the event.
• 株式会社ミズカン Holdings (Mizkan Holdings)minorGTM or Marketing Partner · 1 April 2024Online seminar speaker for Mizkan Group employees on entrepreneurship and career transformation. Employee engagement initiative.
• 一般社团法人ワーカルラボ (Wacal Lab)coreStrategic or Co-development Partner · 14 March 2024Co-host organization for FEMTECH& project. Jointly organized first major project: わかる！助かる！フェムテック展in 和歌山市 at AEON Mall Wakayama with 500+ visitors. Continued partnership for Local Woman's Health Lab Symposium in Kyoto.
• 合同会社五方よし (Go-Ho-Yoshi LLC)coreStrategic or Co-development Partner · 1 December 2023MOU (basic agreement) signed for cooperation in NCT concept social implementation. Partnership focuses on cancer screening democratization and joint event planning/support. Five-point partnership aimed at improving cancer screening accessibility.

Scale indicators4 records

Recent moves6 records

Expansion highlights12 records

Broad incumbents

• iCAD: Provider of AI-based breast cancer detection and risk-stratification software used alongside mammography — adjacent technology player competing for the same screening-quality and early-detection value proposition.
• Philips: Global medtech incumbent with breast imaging (ultrasound, mammography) and patient monitoring portfolio — provides the established, well-capitalized alternative that any non-clinical breast screening entrant must defend against.
• Volpara Health Technologies: Software-focused breast cancer screening analytics and risk-assessment vendor — comparable analytics/digital-health layer that overlaps with NCT's aspiration to deliver quantitative, accessible breast cancer risk insight.
• Hologic: Global leader in mammography and breast cancer diagnostics (Genius 3D Mammography, Brevera). Broad incumbent in breast cancer screening that any non-mammography entrant like NCT must position against.
• GE HealthCare: Major incumbent in breast imaging (ultrasound, mammography, contrast-enhanced mammography) — comparable adjacent modality (ultrasound) used by NCT and the same target use case (breast cancer screening).

Direct peers

• Braster: Poland-based company behind Braster Pro, a contact breast cancer screening device for at-home and non-clinical use — closely aligned pain-free, non-mammography breast screening concept targeting women who skip conventional screening.
• UE LifeSciences: US/India-based company offering 'iBreastExam' and similar no-touch breast scanning devices deployed in pharmacies and non-clinical settings — direct analogue of NCT's non-medical-facility breast cancer screening distribution thesis.
• Lily MedTech: Japanese startup developing a ring-shaped ultrasound device for breast cancer screening — same Japan-based mission of replacing painful mammography with more accessible, patient-friendly screening technology.
• Pickles (ピクルス): Japanese femtech startup offering at-home cervical cancer self-screening test kits — comparable direct-to-consumer, at-home/outside-hospital cancer screening model targeting Japanese women who avoid conventional screening.

Emerging players

• Niramai Health Analytix: India-based startup offering non-touch, privacy-aware breast cancer screening deployable in non-clinical settings — emerging-market analogue pursuing the same 'screening outside the hospital' thesis as NCT.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Instagraminstagram.com/100_onewo

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about 100